問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberC4391024
NCT Number(ClinicalTrials.gov Identfier)NCT06760637
Active

2025-02-11 - 2038-02-19

Phase III

Recruiting8

ICD-10C50.011

Malignant neoplasm of nipple and areola, right female breast

ICD-10C50.012

Malignant neoplasm of nipple and areola, left female breast

ICD-10C50.019

Malignant neoplasm of nipple and areola, unspecified female breast

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9174.0

Malignant neoplasm of female breast, nipple and areola

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

Principal Investigator 張源清 無
MacKay Memorial Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Shin-Cheh Chen 無
Linkou Chang Gung Medical Foundation

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator YEN-SHEN LU 無
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Jih-Hsiang Lee 無
National Taiwan University Hospital Hsin-Chu Branch

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ling-Ming Tseng 無
Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 鍾奇峰 Division of Hematology & Oncology
Koo Foundation Sun Yat-Sen Cancer Center

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Pang Chung
National Taiwan University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chih-Chiang Hung
Taichung Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Breast Cancer

Objectives

The study aimed to evaluate whether PF-07220060 plus letrozole, as a substitute for cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6i) (with trial administrator options of abemaciclib, palbociclib, or ribociclib), plus letrozole, could improve clinical outcomes in participants with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (a/mBC) who had not previously received any systemic anticancer therapy for advanced/metastatic disease.

Test Drug

Tablets

Capsules

Tablets

Tablets

Tablets

Active Ingredient

PF-07220060
PD-0332991-00
abemaciclib
Ribociclib
Letrozole

Dosage Form

110
909
110
110
110

Dosage

100 mg
75mg, 100mg, 125mg
50mg, 100mg, 150mg
200mg
2.5mg

Endpoints

Compare the efficacy of PF-07220060 combined with letrozole (Group A) versus CDK4/6i (administrator choice: abemaciclib, palbociclib, or ribociclib) combined with letrozole (Group B) in terms of progression-free survival (PFS).

Inclution Criteria

Inclusion Criteria:

Histological confirmation of breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent.
Documented estrogen receptor (ER) and/or progesterone receptor (PR)-positive tumor
Documented HER2-negative tumor
Previously untreated with any systemic anticancer therapy for their locally advanced or metastatic disease.
Measurable disease or non-measurable bone only disease as defined by RECIST version 1.1

Exclusion Criteria

Exclusion Criteria:

In visceral crisis at risk of immediately life-threatening complications in the short term.
Current or past history of central nervous system metastases.
Have received prior (neo)adjuvant endocrine therapy (ET) and had recurrence during or within 12 months after the last dose of ET.
Have received prior (neo)adjuvant CDK4/6i and had recurrence during or within 12 months after the last dose of CDK4/6i.
Inadequate renal function, hepatic dysfunction, or hematologic abnormalities.

The Estimated Number of Participants

  • Taiwan

    60 participants

  • Global

    1020 participants

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB